精研科技(300709.SZ):擬向多家銀行和金融機構申請不超25億元綜合授信額度
格隆匯12月8日丨精研科技(300709.SZ)公佈,公司第三屆董事會第六次會議決議,審議通過《關於向銀行申請綜合授信額度的議案》,該議案尚需提交公司股東大會審議。
為保證現金流量充足,並滿足公司長期經營發展需要,公司及其子公司擬向多家銀行和金融機構申請總額不超過(含)25億元的綜合授信額度,包括但不限於南京銀行股份有限公司常州分行、中國銀行股份有限公司常州鐘樓支行等,上述授信額度可在授信期限內循環使用。授信期限自股東大會審議通過之日起兩年內有效。公司董事會擬提請公司股東大會授權公司董事長王明喜先生或其指定的授權代理人代表公司審核批准並簽署綜合授信額度內的各項法律文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.